夏威夷的一名法官裁定，FDA 在没有正当理由的情况下对米非司酮保持严格规定违反了法律。 A Hawaii judge ruled the FDA broke the law by keeping strict rules on mifepristone without proper justification.

夏威夷一名联邦法官裁定林业发展局违反法律,维持关于mifepristone的限制性条例,认为该机构没有为处方、药房认证和强制性咨询表格等规则提供合理理由。 A federal judge in Hawaii ruled the FDA violated the law by maintaining restrictive regulations on mifepristone, finding the agency failed to provide a reasoned justification for rules like prescriber and pharmacy certification and mandatory counseling forms. 此项决定源于美国公民和自由联盟的一项诉讼,是在持续的法律和政治斗争中作出的,争取获得该药物,25年来,该药物一直被视为安全和有效的。 The decision, stemming from an ACLU lawsuit, comes amid ongoing legal and political battles over access to the drug, which has been deemed safe and effective for 25 years. 尽管法官命令林业发展局重新考虑被忽视的证据,但目前的限制措施仍然存在。 While the judge ordered the FDA to reconsider ignored evidence, current restrictions remain in place. 该案始于2017年,涉及多个行政部门,凸显出对规则不成比例地影响低收入和农村患者的关切。 The case, which began in 2017 and spans multiple administrations, highlights concerns that the rules disproportionately affect low-income and rural patients. 美国食品和药物管理局此前已取消了亲自接收的要求, 但其他障碍仍然存在. The FDA previously removed the in-person pickup requirement, but other barriers persist. 这项裁决强调,尽管司法部没有发表意见,但人们日益严格地审查米费普斯顿的条例,特别是在潜在的共和党领导下。 The ruling underscores growing scrutiny of mifepristone’s regulation, especially under potential Republican leadership, though the Justice Department has not commented. 夏威夷允许堕胎,直到胎儿存活,并且病人的生命或健康面临危险。 Hawaii allows abortion until fetal viability and in cases where a patient’s life or health is at risk.